Mentalization-Based Treatment with and without Competitive Memory Training for patients with borderline personality disorder: randomnized controlled trial
- Conditions
- borderline10034726
- Registration Number
- NL-OMON39537
- Lead Sponsor
- Stichting Rivierduinen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Patients are registered with the Rivierduinen care program Personality Disorders
Aged between 18 and 65 years
Confirmation of the primary diagnosis of borderline personality disorder using the international personality disorder examination(IPDE) for DSM-IV
BPDSI-IV score bigger than 20
informed consent
Insufficient command of the Dutch language
Severe comorbid psychopathology such as: psychotic disorders(except short, reactive psychotic episodes, that can be part of the clinical picture of BPD), bipolar disorder, dissociative identity disorder, antisocial personality disorder, attention deficit hyperactivity disorder, addiction of such severity that clinical detoxification is indicated (after which entering treatment is possible), psychiatric disorders secondary to medical conditions and mental retardation. Comorbid axis 1 and axis 2 disorders are allowed, as is medication use.
Simultaneous participation in another specific psychiatric treatment, except medication.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary outcome measure is the frequency and severity of borderline<br /><br>personality symptomatology as assessed with the Borderline Personality<br /><br>Disorder Severity Index (BPDSI-IV), a semi-structured interview. </p><br>
- Secondary Outcome Measures
Name Time Method <p>A secondary aim is to investigate whether this enhanced effectiveness is indeed<br /><br>mediated by changes in self-esteem and/or changes in a bias for negative<br /><br>emotional information.<br /><br>Further it is tested whether a variation in the oxytocin receptor gene<br /><br>moderates the outcomes.</p><br>